By Josh Beckerman

Mylan NV (MYL) said a federal appeals court affirmed prior decisions in the company's favor in a patent dispute with Teva Pharmaceutical Industries Ltd. (TEVA).

Last year, Mylan received U.S. Food and Drug Administration approval to sell glatiramer acetate injection, a generic version of Teva's blockbuster Copaxone drug, which treats multiple sclerosis.

Mylan said the appeals court affirmed that Teva's 40 mg/ML dosing patents are invalid.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 12, 2018 13:15 ET (17:15 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024 Teva Pharmaceutical Indu...のチャートをもっと見るにはこちらをクリック
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024 Teva Pharmaceutical Indu...のチャートをもっと見るにはこちらをクリック